Trial Profile

A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bizalimogene ralaplasmid (Primary) ; Imiquimod
Indications Human papillomavirus infections; Vulvar intraepithelial neoplasia
Focus Proof of concept; Therapeutic Use
Sponsors Inovio Pharmaceuticals

15 Nov 2021 According to an Inovio Pharmaceuticals media release, results from this trial will be presented at the 34th International Papillomavirus Conference (IPVC) 2021.
01 Sep 2021 Status changed from active, no longer recruiting to completed.
06 Jan 2021 Results presented in an Inovio AS Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com